function from the phased array system toolbox Search Results


belatacept  (Florman Family Foundation)
90
Florman Family Foundation belatacept
Summary of findings for the main comparison
Belatacept, supplied by Florman Family Foundation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/function+from+the+phased+array+system+toolbox/pmc06486198-1051-31-4?v=Florman+Family+Foundation
Average 90 stars, based on 1 article reviews
belatacept - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
exponential one-phase decay function  (GraphPad Software Inc)
90
GraphPad Software Inc exponential one-phase decay function
Summary of findings for the main comparison
Exponential One Phase Decay Function, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/function+from+the+phased+array+system+toolbox/pm33524256-450-11-15?v=GraphPad+Software+Inc
Average 90 stars, based on 1 article reviews
exponential one-phase decay function - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
function generator afg3051c  (Tektronix inc)
90
Tektronix inc function generator afg3051c
Summary of findings for the main comparison
Function Generator Afg3051c, supplied by Tektronix inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/function+from+the+phased+array+system+toolbox/10__1016_slash_j__nima__2024__169820-215-9-12?v=Tektronix+inc
Average 90 stars, based on 1 article reviews
function generator afg3051c - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
pcm sp50  (Rubitherm Technologies GmbH)
90
Rubitherm Technologies GmbH pcm sp50
Summary of findings for the main comparison
Pcm Sp50, supplied by Rubitherm Technologies GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/function+from+the+phased+array+system+toolbox/10__1080_slash_19401493__2019__1657953-143-12-11?v=Rubitherm+Technologies+GmbH
Average 90 stars, based on 1 article reviews
pcm sp50 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
4d flow phase-contrast magnetic resonance imaging magnetom skyra  (Siemens AG)
90
Siemens AG 4d flow phase-contrast magnetic resonance imaging magnetom skyra
Summary of findings for the main comparison
4d Flow Phase Contrast Magnetic Resonance Imaging Magnetom Skyra, supplied by Siemens AG, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/function+from+the+phased+array+system+toolbox/pmc05698485-106-7-14?v=Siemens+AG
Average 90 stars, based on 1 article reviews
4d flow phase-contrast magnetic resonance imaging magnetom skyra - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
nonlinear function one phase decay from graphpad prism 7.0  (GraphPad Software Inc)
90
GraphPad Software Inc nonlinear function one phase decay from graphpad prism 7.0
Summary of findings for the main comparison
Nonlinear Function One Phase Decay From Graphpad Prism 7.0, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/function+from+the+phased+array+system+toolbox/pm37429918-342-12-11?v=GraphPad+Software+Inc
Average 90 stars, based on 1 article reviews
nonlinear function one phase decay from graphpad prism 7.0 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
one-phase exponential decay functions  (GraphPad Software Inc)
90
GraphPad Software Inc one-phase exponential decay functions
Summary of findings for the main comparison
One Phase Exponential Decay Functions, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/function+from+the+phased+array+system+toolbox/pm37358244__nn3c01599_si_001-105-6-18?v=GraphPad+Software+Inc
Average 90 stars, based on 1 article reviews
one-phase exponential decay functions - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
fmri data  (SCHOTT)
90
SCHOTT fmri data
Trial structure and timing at study and test and behavioral response categories from the combination of stem-completion responses and study-list-membership judgments. The relevant contrasts at study were between remembered-and-forgotten and primed-and-forgotten response categories. The relevant contrast at test (used for an inclusive masking analysis of the study-phase data) was between the correct-rejection and primed response categories (Schott et al., 2005). False alarms were rare and did not yield enough observations for <t>fMRI</t> analysis.
Fmri Data, supplied by SCHOTT, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/function+from+the+phased+array+system+toolbox/pmc06675357-137-17-23?v=SCHOTT
Average 90 stars, based on 1 article reviews
fmri data - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
rqmd phase-space distribution  (PhaseSpace Inc)
90
PhaseSpace Inc rqmd phase-space distribution
Trial structure and timing at study and test and behavioral response categories from the combination of stem-completion responses and study-list-membership judgments. The relevant contrasts at study were between remembered-and-forgotten and primed-and-forgotten response categories. The relevant contrast at test (used for an inclusive masking analysis of the study-phase data) was between the correct-rejection and primed response categories (Schott et al., 2005). False alarms were rare and did not yield enough observations for <t>fMRI</t> analysis.
Rqmd Phase Space Distribution, supplied by PhaseSpace Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/function+from+the+phased+array+system+toolbox/10__1146_slash_annurev__nucl__49__1__529-637-7-8?v=PhaseSpace+Inc
Average 90 stars, based on 1 article reviews
rqmd phase-space distribution - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
matlab signal processing toolbox  (MathWorks Inc)
98
MathWorks Inc matlab signal processing toolbox
Trial structure and timing at study and test and behavioral response categories from the combination of stem-completion responses and study-list-membership judgments. The relevant contrasts at study were between remembered-and-forgotten and primed-and-forgotten response categories. The relevant contrast at test (used for an inclusive masking analysis of the study-phase data) was between the correct-rejection and primed response categories (Schott et al., 2005). False alarms were rare and did not yield enough observations for <t>fMRI</t> analysis.
Matlab Signal Processing Toolbox, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/function+from+the+phased+array+system+toolbox/pmc02712260-89-11-16?v=MathWorks+Inc
Average 98 stars, based on 1 article reviews
matlab signal processing toolbox - by Bioz Stars, 2026-08
98/100 stars
  Buy from Supplier
phase e coli dh5α  (ATCC)
93
ATCC phase e coli dh5α
Bacterial strains and plasmids
Phase E Coli Dh5α, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/function+from+the+phased+array+system+toolbox/pmc06715845-210-11-18?v=ATCC
Average 93 stars, based on 1 article reviews
phase e coli dh5α - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
α-methylbenzylamine functionalized crown-ether-appended calix[4]arene derived phase transfer catalyst  (Pragati Textile)
90
Pragati Textile α-methylbenzylamine functionalized crown-ether-appended calix[4]arene derived phase transfer catalyst
Bacterial strains and plasmids
α Methylbenzylamine Functionalized Crown Ether Appended Calix[4]Arene Derived Phase Transfer Catalyst, supplied by Pragati Textile, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/function+from+the+phased+array+system+toolbox/pm37850687-15-16-2?v=Pragati+Textile
Average 90 stars, based on 1 article reviews
α-methylbenzylamine functionalized crown-ether-appended calix[4]arene derived phase transfer catalyst - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


Summary of findings for the main comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Belatacept for kidney transplant recipients

doi: 10.1002/14651858.CD010699.pub2

Figure Lengend Snippet: Summary of findings for the main comparison

Article Snippet: [ Google Scholar ] Florman S, Durrbach A, Larsen C, Medina‐Pestana J, Vanrenterghem Y, Vincenti F, et al. Outcomes as a function of donor criteria from a phase iii study of belatacept vs cyclosporine in kidney transplantation (BENEFIT‐EXT) [abstract no: 1773] .

Techniques: Comparison, Virus, Control

Comparison 1 Any dosage belatacept versus calcineurin inhibitor (CNI), Outcome 1 Recipient and kidney survival.

Journal: The Cochrane Database of Systematic Reviews

Article Title: Belatacept for kidney transplant recipients

doi: 10.1002/14651858.CD010699.pub2

Figure Lengend Snippet: Comparison 1 Any dosage belatacept versus calcineurin inhibitor (CNI), Outcome 1 Recipient and kidney survival.

Article Snippet: [ Google Scholar ] Florman S, Durrbach A, Larsen C, Medina‐Pestana J, Vanrenterghem Y, Vincenti F, et al. Outcomes as a function of donor criteria from a phase iii study of belatacept vs cyclosporine in kidney transplantation (BENEFIT‐EXT) [abstract no: 1773] .

Techniques: Comparison

Comparison 1 Any dosage belatacept versus calcineurin inhibitor (CNI), Outcome 2 Surviving with a functioning transplant.

Journal: The Cochrane Database of Systematic Reviews

Article Title: Belatacept for kidney transplant recipients

doi: 10.1002/14651858.CD010699.pub2

Figure Lengend Snippet: Comparison 1 Any dosage belatacept versus calcineurin inhibitor (CNI), Outcome 2 Surviving with a functioning transplant.

Article Snippet: [ Google Scholar ] Florman S, Durrbach A, Larsen C, Medina‐Pestana J, Vanrenterghem Y, Vincenti F, et al. Outcomes as a function of donor criteria from a phase iii study of belatacept vs cyclosporine in kidney transplantation (BENEFIT‐EXT) [abstract no: 1773] .

Techniques: Comparison

Comparison 1 Any dosage belatacept versus calcineurin inhibitor (CNI), Outcome 3 Acute rejection and chronic kidney scarring.

Journal: The Cochrane Database of Systematic Reviews

Article Title: Belatacept for kidney transplant recipients

doi: 10.1002/14651858.CD010699.pub2

Figure Lengend Snippet: Comparison 1 Any dosage belatacept versus calcineurin inhibitor (CNI), Outcome 3 Acute rejection and chronic kidney scarring.

Article Snippet: [ Google Scholar ] Florman S, Durrbach A, Larsen C, Medina‐Pestana J, Vanrenterghem Y, Vincenti F, et al. Outcomes as a function of donor criteria from a phase iii study of belatacept vs cyclosporine in kidney transplantation (BENEFIT‐EXT) [abstract no: 1773] .

Techniques: Comparison

Comparison 1 Any dosage belatacept versus calcineurin inhibitor (CNI), Outcome 4 Kidney function, blood pressure and lipids.

Journal: The Cochrane Database of Systematic Reviews

Article Title: Belatacept for kidney transplant recipients

doi: 10.1002/14651858.CD010699.pub2

Figure Lengend Snippet: Comparison 1 Any dosage belatacept versus calcineurin inhibitor (CNI), Outcome 4 Kidney function, blood pressure and lipids.

Article Snippet: [ Google Scholar ] Florman S, Durrbach A, Larsen C, Medina‐Pestana J, Vanrenterghem Y, Vincenti F, et al. Outcomes as a function of donor criteria from a phase iii study of belatacept vs cyclosporine in kidney transplantation (BENEFIT‐EXT) [abstract no: 1773] .

Techniques: Comparison

Comparison 1 Any dosage belatacept versus calcineurin inhibitor (CNI), Outcome 5 Malignancy.

Journal: The Cochrane Database of Systematic Reviews

Article Title: Belatacept for kidney transplant recipients

doi: 10.1002/14651858.CD010699.pub2

Figure Lengend Snippet: Comparison 1 Any dosage belatacept versus calcineurin inhibitor (CNI), Outcome 5 Malignancy.

Article Snippet: [ Google Scholar ] Florman S, Durrbach A, Larsen C, Medina‐Pestana J, Vanrenterghem Y, Vincenti F, et al. Outcomes as a function of donor criteria from a phase iii study of belatacept vs cyclosporine in kidney transplantation (BENEFIT‐EXT) [abstract no: 1773] .

Techniques: Comparison

Comparison 1 Any dosage belatacept versus calcineurin inhibitor (CNI), Outcome 6 Infections.

Journal: The Cochrane Database of Systematic Reviews

Article Title: Belatacept for kidney transplant recipients

doi: 10.1002/14651858.CD010699.pub2

Figure Lengend Snippet: Comparison 1 Any dosage belatacept versus calcineurin inhibitor (CNI), Outcome 6 Infections.

Article Snippet: [ Google Scholar ] Florman S, Durrbach A, Larsen C, Medina‐Pestana J, Vanrenterghem Y, Vincenti F, et al. Outcomes as a function of donor criteria from a phase iii study of belatacept vs cyclosporine in kidney transplantation (BENEFIT‐EXT) [abstract no: 1773] .

Techniques: Comparison

Comparison 1 Any dosage belatacept versus calcineurin inhibitor (CNI), Outcome 7 Diabetes and use of blood pressure medicines.

Journal: The Cochrane Database of Systematic Reviews

Article Title: Belatacept for kidney transplant recipients

doi: 10.1002/14651858.CD010699.pub2

Figure Lengend Snippet: Comparison 1 Any dosage belatacept versus calcineurin inhibitor (CNI), Outcome 7 Diabetes and use of blood pressure medicines.

Article Snippet: [ Google Scholar ] Florman S, Durrbach A, Larsen C, Medina‐Pestana J, Vanrenterghem Y, Vincenti F, et al. Outcomes as a function of donor criteria from a phase iii study of belatacept vs cyclosporine in kidney transplantation (BENEFIT‐EXT) [abstract no: 1773] .

Techniques: Comparison

Comparison 2 High versus low dosage belatacept, Outcome 1 Recipient and kidney survival.

Journal: The Cochrane Database of Systematic Reviews

Article Title: Belatacept for kidney transplant recipients

doi: 10.1002/14651858.CD010699.pub2

Figure Lengend Snippet: Comparison 2 High versus low dosage belatacept, Outcome 1 Recipient and kidney survival.

Article Snippet: [ Google Scholar ] Florman S, Durrbach A, Larsen C, Medina‐Pestana J, Vanrenterghem Y, Vincenti F, et al. Outcomes as a function of donor criteria from a phase iii study of belatacept vs cyclosporine in kidney transplantation (BENEFIT‐EXT) [abstract no: 1773] .

Techniques: Comparison

Comparison 2 High versus low dosage belatacept, Outcome 2 Surviving with a functioning transplant.

Journal: The Cochrane Database of Systematic Reviews

Article Title: Belatacept for kidney transplant recipients

doi: 10.1002/14651858.CD010699.pub2

Figure Lengend Snippet: Comparison 2 High versus low dosage belatacept, Outcome 2 Surviving with a functioning transplant.

Article Snippet: [ Google Scholar ] Florman S, Durrbach A, Larsen C, Medina‐Pestana J, Vanrenterghem Y, Vincenti F, et al. Outcomes as a function of donor criteria from a phase iii study of belatacept vs cyclosporine in kidney transplantation (BENEFIT‐EXT) [abstract no: 1773] .

Techniques: Comparison

Comparison 2 High versus low dosage belatacept, Outcome 3 Acute rejection and chronic kidney scarring.

Journal: The Cochrane Database of Systematic Reviews

Article Title: Belatacept for kidney transplant recipients

doi: 10.1002/14651858.CD010699.pub2

Figure Lengend Snippet: Comparison 2 High versus low dosage belatacept, Outcome 3 Acute rejection and chronic kidney scarring.

Article Snippet: [ Google Scholar ] Florman S, Durrbach A, Larsen C, Medina‐Pestana J, Vanrenterghem Y, Vincenti F, et al. Outcomes as a function of donor criteria from a phase iii study of belatacept vs cyclosporine in kidney transplantation (BENEFIT‐EXT) [abstract no: 1773] .

Techniques: Comparison

Comparison 2 High versus low dosage belatacept, Outcome 4 Kidney function, blood pressure and lipids.

Journal: The Cochrane Database of Systematic Reviews

Article Title: Belatacept for kidney transplant recipients

doi: 10.1002/14651858.CD010699.pub2

Figure Lengend Snippet: Comparison 2 High versus low dosage belatacept, Outcome 4 Kidney function, blood pressure and lipids.

Article Snippet: [ Google Scholar ] Florman S, Durrbach A, Larsen C, Medina‐Pestana J, Vanrenterghem Y, Vincenti F, et al. Outcomes as a function of donor criteria from a phase iii study of belatacept vs cyclosporine in kidney transplantation (BENEFIT‐EXT) [abstract no: 1773] .

Techniques: Comparison

Comparison 2 High versus low dosage belatacept, Outcome 5 Malignancy.

Journal: The Cochrane Database of Systematic Reviews

Article Title: Belatacept for kidney transplant recipients

doi: 10.1002/14651858.CD010699.pub2

Figure Lengend Snippet: Comparison 2 High versus low dosage belatacept, Outcome 5 Malignancy.

Article Snippet: [ Google Scholar ] Florman S, Durrbach A, Larsen C, Medina‐Pestana J, Vanrenterghem Y, Vincenti F, et al. Outcomes as a function of donor criteria from a phase iii study of belatacept vs cyclosporine in kidney transplantation (BENEFIT‐EXT) [abstract no: 1773] .

Techniques: Comparison

Comparison 2 High versus low dosage belatacept, Outcome 6 Infections.

Journal: The Cochrane Database of Systematic Reviews

Article Title: Belatacept for kidney transplant recipients

doi: 10.1002/14651858.CD010699.pub2

Figure Lengend Snippet: Comparison 2 High versus low dosage belatacept, Outcome 6 Infections.

Article Snippet: [ Google Scholar ] Florman S, Durrbach A, Larsen C, Medina‐Pestana J, Vanrenterghem Y, Vincenti F, et al. Outcomes as a function of donor criteria from a phase iii study of belatacept vs cyclosporine in kidney transplantation (BENEFIT‐EXT) [abstract no: 1773] .

Techniques: Comparison

Comparison 2 High versus low dosage belatacept, Outcome 7 Diabetes and use of blood pressure medicines.

Journal: The Cochrane Database of Systematic Reviews

Article Title: Belatacept for kidney transplant recipients

doi: 10.1002/14651858.CD010699.pub2

Figure Lengend Snippet: Comparison 2 High versus low dosage belatacept, Outcome 7 Diabetes and use of blood pressure medicines.

Article Snippet: [ Google Scholar ] Florman S, Durrbach A, Larsen C, Medina‐Pestana J, Vanrenterghem Y, Vincenti F, et al. Outcomes as a function of donor criteria from a phase iii study of belatacept vs cyclosporine in kidney transplantation (BENEFIT‐EXT) [abstract no: 1773] .

Techniques: Comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Belatacept for kidney transplant recipients

doi: 10.1002/14651858.CD010699.pub2

Figure Lengend Snippet:

Article Snippet: [ Google Scholar ] Florman S, Durrbach A, Larsen C, Medina‐Pestana J, Vanrenterghem Y, Vincenti F, et al. Outcomes as a function of donor criteria from a phase iii study of belatacept vs cyclosporine in kidney transplantation (BENEFIT‐EXT) [abstract no: 1773] .

Techniques: Transplantation Assay, Clinical Proteomics

Any dosage belatacept versus calcineurin inhibitor (CNI)

Journal: The Cochrane Database of Systematic Reviews

Article Title: Belatacept for kidney transplant recipients

doi: 10.1002/14651858.CD010699.pub2

Figure Lengend Snippet: Any dosage belatacept versus calcineurin inhibitor (CNI)

Article Snippet: [ Google Scholar ] Florman S, Durrbach A, Larsen C, Medina‐Pestana J, Vanrenterghem Y, Vincenti F, et al. Outcomes as a function of donor criteria from a phase iii study of belatacept vs cyclosporine in kidney transplantation (BENEFIT‐EXT) [abstract no: 1773] .

Techniques: Infection

Trial structure and timing at study and test and behavioral response categories from the combination of stem-completion responses and study-list-membership judgments. The relevant contrasts at study were between remembered-and-forgotten and primed-and-forgotten response categories. The relevant contrast at test (used for an inclusive masking analysis of the study-phase data) was between the correct-rejection and primed response categories (Schott et al., 2005). False alarms were rare and did not yield enough observations for fMRI analysis.

Journal: The Journal of Neuroscience

Article Title: Neuroanatomical Dissociation of Encoding Processes Related to Priming and Explicit Memory

doi: 10.1523/JNEUROSCI.2402-05.2006

Figure Lengend Snippet: Trial structure and timing at study and test and behavioral response categories from the combination of stem-completion responses and study-list-membership judgments. The relevant contrasts at study were between remembered-and-forgotten and primed-and-forgotten response categories. The relevant contrast at test (used for an inclusive masking analysis of the study-phase data) was between the correct-rejection and primed response categories (Schott et al., 2005). False alarms were rare and did not yield enough observations for fMRI analysis.

Article Snippet: The fMRI data reported here were collected during the study phases of an experiment from which the test-phase fMRI data are published ( Schott et al., 2005 ).

Techniques:

Bacterial strains and plasmids

Journal: Applied and Environmental Microbiology

Article Title: New Shuttle Vectors for Real-Time Gene Expression Analysis in Multidrug-Resistant Acinetobacter Species: In Vitro and In Vivo Responses to Environmental Stressors

doi: 10.1128/AEM.01334-19

Figure Lengend Snippet: Bacterial strains and plasmids

Article Snippet: Accordingly, all pLPV plasmids could be extracted with good yields from early-stationary-phase E. coli DH5α and A. baumannii ATCC 19606 T cells, attaining up to 1.65 and 0.45 μg of DNA per milliliter of culture at an optical density at 600 nm (OD 600 ) of 1 (Table S1).

Techniques: Plasmid Preparation, Cloning, Expressing, Low Copy Number, Clone Assay, Binding Assay

Transformation efficiency and stability of pLPV plasmids and antibiotic concentrations required for their selection

Journal: Applied and Environmental Microbiology

Article Title: New Shuttle Vectors for Real-Time Gene Expression Analysis in Multidrug-Resistant Acinetobacter Species: In Vitro and In Vivo Responses to Environmental Stressors

doi: 10.1128/AEM.01334-19

Figure Lengend Snippet: Transformation efficiency and stability of pLPV plasmids and antibiotic concentrations required for their selection

Article Snippet: Accordingly, all pLPV plasmids could be extracted with good yields from early-stationary-phase E. coli DH5α and A. baumannii ATCC 19606 T cells, attaining up to 1.65 and 0.45 μg of DNA per milliliter of culture at an optical density at 600 nm (OD 600 ) of 1 (Table S1).

Techniques: Transformation Assay, Plasmid Preparation

Physical and functional map of pLPV1Z (A), pLPV2Z (B), and pLPV3Z (C) promoter-probe vectors. The nucleotide sequence upstream of the reporter gene is shown for each vector. In all vectors, the ribosome binding site (RBS) is provided by the canonical sequence 5′-AAAGAGGAGAAA-3′, preceded by stop codons in the three reading frames (red). Unique cutter restriction enzymes are indicated in bold. Nomenclature: ble, Zeo resistance gene; aacC1, Gm resistance gene; ori ColE1-like, ColE1-derived origin of replication for E. coli; oriAb, origin of replication for Acinetobacter spp. All genes are reported in scale over the total length of the vector. Images were obtained by Snapgene software (GSL Biotech).

Journal: Applied and Environmental Microbiology

Article Title: New Shuttle Vectors for Real-Time Gene Expression Analysis in Multidrug-Resistant Acinetobacter Species: In Vitro and In Vivo Responses to Environmental Stressors

doi: 10.1128/AEM.01334-19

Figure Lengend Snippet: Physical and functional map of pLPV1Z (A), pLPV2Z (B), and pLPV3Z (C) promoter-probe vectors. The nucleotide sequence upstream of the reporter gene is shown for each vector. In all vectors, the ribosome binding site (RBS) is provided by the canonical sequence 5′-AAAGAGGAGAAA-3′, preceded by stop codons in the three reading frames (red). Unique cutter restriction enzymes are indicated in bold. Nomenclature: ble, Zeo resistance gene; aacC1, Gm resistance gene; ori ColE1-like, ColE1-derived origin of replication for E. coli; oriAb, origin of replication for Acinetobacter spp. All genes are reported in scale over the total length of the vector. Images were obtained by Snapgene software (GSL Biotech).

Article Snippet: Accordingly, all pLPV plasmids could be extracted with good yields from early-stationary-phase E. coli DH5α and A. baumannii ATCC 19606 T cells, attaining up to 1.65 and 0.45 μg of DNA per milliliter of culture at an optical density at 600 nm (OD 600 ) of 1 (Table S1).

Techniques: Functional Assay, Sequencing, Plasmid Preparation, Binding Assay, Derivative Assay, Software